<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Extraction extraction-result-71 - Theorizer</title>
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/font-awesome/5.15.1/css/all.min.css">
    <link rel="stylesheet" href="../style.css">
</head>
<body>
    <div class="header">
        <a href="../index.html"><i class="fas fa-flask"></i> Theorizer</a>
    </div>

    <div class="content">
        <h1>Extracted Data Details for extraction-result-71</h1>

        <div class="section">
            <h2>Extracted Data (Header)</h2>
            <div class="info-section">
                <p><strong>Extraction ID:</strong> extraction-result-71</p>
                <p><strong>Extraction Schema Used (ID):</strong> <a href="../schemas/extraction-schema-5.html">extraction-schema-5</a></p>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of anti-PD1 immunotherapy treatment duration for melanoma, including treatment protocols, patient response categories, outcomes by duration and response level, and comparisons between different treatment duration strategies.</div>
                <p><strong>Paper ID:</strong> paper-e981c163543110d68b26697a6cb2307a9ebad5fa</p>
                <p><strong>Paper Title:</strong> <a href="https://www.semanticscholar.org/paper/e981c163543110d68b26697a6cb2307a9ebad5fa" target="_blank">Efficacy and Safety Outcomes in Patients With Advanced Melanoma Who Discontinued Treatment With Nivolumab and Ipilimumab Because of Adverse Events: A Pooled Analysis of Randomized Phase II and III Trials.</a></p>
                <p><strong>Paper Venue:</strong> Journal of Clinical Oncology</p>
                <p><strong>Paper TL;DR:</strong> Efficacy outcomes seemed similar between patients who discontinued nivolumab plus ipilimumab treatment because of AEs during the induction phase and those who did not discontinue because of aEs, suggesting that many patients may continue to derive benefit from combination therapy even after discontinuation.</p>
                <p><strong>Cost:</strong> 0.014</p>
            </div>
        </div>

        <div class="section">
            <h2>Extracted Data (Details)</h2>
            <div class="extraction-instance-container" id="e71.0">
                <h3 class="extraction-instance">Extracted Data Instance 0 (e71.0)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of anti-PD1 immunotherapy treatment duration for melanoma, including treatment protocols, patient response categories, outcomes by duration and response level, and comparisons between different treatment duration strategies.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>CheckMate pooled AE discontinuation analysis</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Efficacy and Safety Outcomes in Patients With Advanced Melanoma Who Discontinued Treatment With Nivolumab and Ipilimumab Because of Adverse Events: A Pooled Analysis of Randomized Phase II and III Trials</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>A retrospective pooled analysis of patients from the CheckMate 069 (phase II) and CheckMate 067 (phase III) trials evaluating efficacy and safety outcomes in advanced melanoma patients who discontinued nivolumab + ipilimumab because of treatment-related adverse events, with comparison between early (induction-phase) discontinuation and continuation to maintenance therapy.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>Efficacy and Safety Outcomes in Patients With Advanced Melanoma Who Discontinued Treatment With Nivolumab and Ipilimumab Because of Adverse Events: A Pooled Analysis of Randomized Phase II and III Trials</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>use</td>
                        </tr>
                        <tr>
                            <td><strong>study_type</strong></td>
                            <td>retrospective pooled analysis of randomized phase II and phase III trials</td>
                        </tr>
                        <tr>
                            <td><strong>anti_pd1_agent</strong></td>
                            <td>nivolumab (used in combination with ipilimumab)</td>
                        </tr>
                        <tr>
                            <td><strong>treatment_duration</strong></td>
                            <td>Induction: nivolumab 1 mg/kg + ipilimumab 3 mg/kg every 3 weeks for up to four doses, followed by nivolumab maintenance 3 mg/kg every 2 weeks until progression or unacceptable toxicity; observed/compared durations in cohorts: median 1.4 months (early/induction discontinuation), median 1.5 months (discontinued because of AEs at any time), median 9.4 months (did not discontinue because of AEs; continued to maintenance), with median number of doses: induction-discontinued median 3 doses nivolumab/ipilimumab each (range 1–4); non-discontinued group median 14 nivolumab doses (range 1–58) and 4 ipilimumab doses (range 1–4).</td>
                        </tr>
                        <tr>
                            <td><strong>patient_cohort_size</strong></td>
                            <td>409 randomly assigned to nivolumab + ipilimumab (407 treated); efficacy comparison cohorts: 96 patients who discontinued because of AEs during the induction phase vs 233 patients who did not discontinue because of AEs; safety cohorts: 176 patients who discontinued because of treatment-related AEs at any time vs 231 who did not.</td>
                        </tr>
                        <tr>
                            <td><strong>melanoma_stage</strong></td>
                            <td>Unresectable stage III or stage IV (advanced, metastatic) melanoma; treatment-naive patients.</td>
                        </tr>
                        <tr>
                            <td><strong>response_categories</strong></td>
                            <td>Complete response (CR), Partial response (PR), Stable disease (SD), Progressive disease (PD); Objective response rate (ORR = CR + PR); best overall response and ongoing response status.</td>
                        </tr>
                        <tr>
                            <td><strong>response_assessment_method</strong></td>
                            <td>RECIST version 1.1 (investigator-assessed), baseline, 12 weeks after randomization, then every 6 weeks for first 12 months, then every 12 weeks.</td>
                        </tr>
                        <tr>
                            <td><strong>outcomes_by_duration</strong></td>
                            <td>Key comparative outcomes for early (induction) discontinuation vs continued treatment: ORR 58.3% (56/96; 95% CI 47.8–68.3) for patients who discontinued during induction vs 50.2% (117/233; 95% CI 43.6–56.8) for those who did not (P = .180). Median PFS: 8.4 months (95% CI 5.8–16.7) for induction discontinuation vs 10.8 months (95% CI 5.9–23.0) for non-discontinuation (hazard ratio 0.99; 95% CI 0.72–1.37; P = .966). PFS rates at 18 months: 38% (induction discontinuation) vs 49% (non-discontinued). Median OS: not reached in either group; hazard ratio 0.79 (95% CI 0.54–1.17; P = .2344); OS rates at 18 months: 67% (induction discontinuation) vs 62% (non-discontinued). Median time to response ~2.7 months (range 1.9–10.3) for induction-discontinued vs 2.8 months (1.4–17.1) for non-discontinued. Median duration of response not reached in either group. Overall, no statistically significant differences in PFS or OS by duration (early discontinuation vs continued treatment).</td>
                        </tr>
                        <tr>
                            <td><strong>outcomes_by_response_level</strong></td>
                            <td>Reported counts by best overall response: induction discontinuation (n=96): CR 11 (11.5%), PR 45 (46.9%), SD 18 (18.8%), PD 19 (19.8%), unable to determine 3 (3.1%); non-discontinued (n=233): CR 28 (12.0%), PR 89 (38.2%), SD 25 (10.7%), PD 63 (27.0%), unable to determine 28 (12.0%). Ongoing responders: 36/56 (64.3%) induction-discontinued vs 94/117 (80.3%) non-discontinued. Median duration of response was not reached for any response strata and the paper does not provide survival curves stratified by CR vs PR vs SD; thus no direct numerical OS/PFS by individual response category beyond these counts are provided in this report.</td>
                        </tr>
                        <tr>
                            <td><strong>duration_by_response_findings</strong></td>
                            <td>No definitive evidence that required/optimal treatment duration differs by response level; patients who discontinued early because of AEs (many after achieving responses) had similar ORR, PFS and OS to those who received longer treatment, suggesting durability of response can persist after early discontinuation, but authors caution this is retrospective and potentially confounded (e.g., baseline prognostic imbalances). The authors note the hypothesis that immune-related AEs might signal activated antitumor immunity and these results are consistent with that hypothesis but are not conclusive.</td>
                        </tr>
                        <tr>
                            <td><strong>treatment_discontinuation_reasons</strong></td>
                            <td>Primary reason analyzed: treatment-related adverse events (AEs). Across treated patients (n=407) 176 (43%) discontinued treatment because of AEs at any time; 96 patients (24% of randomly assigned 409) discontinued because of AEs during the induction phase. In the subgroup who did not discontinue because of AEs, other reasons included disease progression (97 of 231; 42% of that subgroup) and other causes. Specific AEs leading to discontinuation (reported between first dose and 30 days after last dose): colitis led to discontinuation in 40 patients (9.8%); increased alanine aminotransferase 20 (4.9%); increased aspartate aminotransferase 18 (4.4%); pneumonitis 10 (2.5%); endocrine disorders collectively 10 (2.5%). Overall, 156/407 (38.3%) had treatment-related AEs that led to discontinuation listed in Table 2 (table uses slightly different denominators in places; paper text reports 176 discontinued because of AEs at any time).</td>
                        </tr>
                        <tr>
                            <td><strong>discontinuation_timing</strong></td>
                            <td>Most grade 3/4 treatment-related AEs occurred during the induction phase. Median number of doses in those who discontinued because of AEs at any time: 3 doses of nivolumab (range 1–45) and 3 doses of ipilimumab (range 1–4); for induction discontinuation median was 3 doses each (range 1–4). Median duration of treatment: 1.5 months (95% CI 1.4–2.1) in patients who discontinued because of AEs at any time; 1.4 months (95% CI 1.2–1.6) in those who discontinued during induction; 9.4 months (95% CI 5.1–14.8) in those who did not discontinue because of AEs. Time to onset of grade 3/4 select AEs: skin 2–3 weeks, GI 6–11 weeks, hepatic 8–10 weeks, endocrine 11–12 weeks. The majority of severe AEs occurred early (during induction), although some AEs can occur later.</td>
                        </tr>
                        <tr>
                            <td><strong>relapse_after_discontinuation</strong></td>
                            <td>Progression data and subsequent therapy: best-response PD rates were 19.8% in induction-discontinued vs 27.0% in non-discontinued. PFS at 18 months was 38% (induction-discontinued) vs 49% (non-discontinued). Median time to subsequent systemic therapy was not reached for the overall AE-discontinued group or non-discontinued group; specifically, median time to subsequent systemic therapy was 25.3 months for patients who discontinued during the induction phase. At 12 months, 59 of 96 (61%) induction-discontinued patients were free of systemic treatment; among those who discontinued because of AEs at any time, 115 of 176 (65%) were free of systemic therapy at 12 months, and among those who did not discontinue because of AEs, 178 of 233 (76%) were free at 12 months. The paper notes a few patients treated with infliximab progressed after an initial response but overall infliximab did not appear to affect development or durability of response in pooled analyses.</td>
                        </tr>
                        <tr>
                            <td><strong>adverse_events_by_duration</strong></td>
                            <td>Grade 3 or 4 AEs clustered in the induction period. In the cohort who discontinued because of AEs at any time, the most frequent grade 3/4 select AEs were GI: diarrhea (20%) and colitis (20%). In the cohort who did not discontinue because of AEs, grade 3/4 hepatic AEs were most frequent (10%). Colitis was the most common AE leading to discontinuation overall (40 patients; 9.8%). Systemic corticosteroids were used for AE management in 91% of patients who discontinued because of an AE vs 55% of patients who did not; infliximab was used in 10% vs 1%. Resolution rates/time (in patients treated with immune-modulating medication): GI 38/38 resolved (100%), median 2.9 weeks (95% CI 1.9–4.3); hepatic 28/28 (100%), median 3.3 weeks (95% CI 2.4–4.4); skin 10/10 (100%), median 5.1 weeks (95% CI 2.1–9.7); endocrine 4/6 (67%) in discontinued group resolved, median 12.1 weeks (wide CI); many endocrine AEs did not meet criteria for resolution because of need for long-term hormone replacement.</td>
                        </tr>
                        <tr>
                            <td><strong>comparison_between_durations</strong></td>
                            <td>Direct comparison between early discontinuation during induction (median ~1.4 months, ~3 doses) and continued treatment (median ~9.4 months, median 14 nivolumab doses) showed no statistically significant difference in PFS or OS: median PFS 8.4 vs 10.8 months (HR 0.99; P = .966); median OS not reached in either group (HR 0.79; P = .2344). ORR was numerically higher in the induction-discontinued group (58.3% vs 50.2%; P = .180) but not statistically significant. Authors caution that these comparisons are retrospective and may be confounded by baseline prognostic differences (fewer M1c and lower LDH in AE-discontinued group).</td>
                        </tr>
                        <tr>
                            <td><strong>recommendations_on_duration</strong></td>
                            <td>Authors do not recommend a specific optimal duration; they conclude that many patients appear to derive durable benefit after early discontinuation because of AEs and that AEs may be a marker of immune activation, but this is not proven. They recommend prospective trials (including randomized discontinuation designs) to define the role and optimal duration of anti-PD-1 maintenance after induction with combination therapy, and note that anti-PD-1 monotherapy may be an option after AE resolution but risk of AE recurrence must be considered.</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Efficacy and Safety Outcomes in Patients With Advanced Melanoma Who Discontinued Treatment With Nivolumab and Ipilimumab Because of Adverse Events: A Pooled Analysis of Randomized Phase II and III Trials.', 'publication_date_yy_mm': '2017-08'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
        </div>

        <div class="section">
            <h2>Potentially Relevant New Papers (mentioned by this paper)</h2>
            <ol>
                <li>Nivolumab and ipilimumab versus ipilimumab in untreated melanoma <em>(Rating: 2)</em></li>
                <li>Combined nivolumab and ipilimumab or monotherapy in untreated melanoma <em>(Rating: 2)</em></li>
                <li>Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial <em>(Rating: 2)</em></li>
                <li>Management of gastrointestinal (GI) toxicity associated with nivolumab (NIVO) plus ipilimumab (IPI) or IPI alone in phase II and phase III trials in advanced melanoma (MEL) <em>(Rating: 1)</em></li>
                <li>Pembrolizumab versus ipilimumab in advanced melanoma <em>(Rating: 1)</em></li>
            </ol>
        </div>

        </div>

    </div>
</body>
</html>